Yujiro is an entrepreneur with over 20 years of experience building companies that have delivered innovative therapies to patients. In August 2015, he launched IDEAYA Biosciences as its first employee and Chief Executive Officer, while serving as an Executive-in-Residence at 5AM Ventures from 2015 to 2018. From 2014 to August 2015, he served as Chief Operating Officer at Flexus Biosciences and FLX Bio, which he led through its acquisition by Bristol-Myers Squibb in April 2015. From 2010 through the approvals of Kyprolis® and Stivarga® and its acquisition by Amgen in October 2013, he was Vice President, Corporate Development and Strategy at Onyx Pharmaceuticals (NASDAQ: ONXX), where he served as Head of Strategy and Strategic Asset Management, and Head of Transactions. From 2002 to 2010, Yujiro served as Vice President, Business Development, Senior Vice President, Business Development, and Chief Business Officer at Enanta Pharmaceuticals (NASDAQ: ENTA), which discovered the protease inhibitors contained in Viekira Pak and Mavyret™, both of which received Breakthrough Therapy designation by the U.S. FDA. He earlier served in roles at McKinsey, ImClone and Columbia Medical School.

Yujiro obtained his M.B.A. at the University of Pennsylvania, his B.A. in chemistry at Colorado College, and did undergraduate studies in chemistry and biology at Oxford University. He serves on the Board of Directors at Xencor (NASDAQ: XNCR) and Expansion Therapeutics, and Board of Visitors at the Moores Cancer Center at the University of California, San Diego.

Mike brings over 20 years of experience in drug discovery. He joined IDEAYA Biosciences as Senior Vice President, Head of Drug Discovery in April 2016, and has served as Senior Vice President and Chief Scientific Officer, Head of Research since February 2018. From 2008 to 2016, Mike was with the Novartis Institutes for Biomedical Research (NIBR) where he served in various leadership roles, including Global Discovery Chemistry Head, Oncology and New Therapeutic Modalities; Head of Chemical Sciences, Emeryville, and Executive Director Oncology Chemistry. Under his leadership at NIBR, several small molecules were advanced towards the clinic, including, PI3K inhibitor BKM120, CSF1R inhibitor BLZ945, V600E mutant B-RAF kinase inhibitor Encorafenib, PIM kinase inhibitor PIM447, ERK inhibitor LTT462, and RAF kinase inhibitor LXH254. From 1993 to 2008, Mike worked at Roche and Syntex (acquired by Roche), where he served in roles of increasing responsibility, including Director, Medicinal Chemistry. At Roche, he led multiple small molecule programs that advanced to the clinic, including first-in-class P2X3 antagonist Gefapixant, now being developed by Merck. Mike is an author on over 60 publications and patents.

Mike obtained his B.Sc. (Hons) from the University of Leicester, and his Ph.D. in Chemistry from the University of Bristol. He completed his postdoctoral fellowship at Oregon State University to continue his research in Chemistry with Professor James D. White.

Julie is a senior biotechnology executive with over 20 years of experience in clinical drug development from pre-clinical through phase 4 and post-marketing studies. She has extensive experience working with regulatory agencies, including the U.S. FDA and the European Medicines Agency (EMA), and in filings of INDs, biologics license applications (BLAs), and special protocol assessments (SPAs). Julie was previously Vice President, Head of US Medical at Bristol-Myers Squibb (NYSE: BMY), overseeing Medical & Health Economic and Outcomes Research activities in support of the Oncology, Immuno-Oncology, Specialty and Cardiovascular marketed portfolios. From 2012 to 2016, she was Executive Vice President and Chief Medical Officer at Five Prime Therapeutics (NASDAQ: FPRX), where she led Clinical, Clinical Operations, Regulatory, Preclinical and Translational and Process Development and was a member of the Executive Committee. From 2010 to 2012, Julie was Vice President, Clinical Development, at Clovis Oncology (NASDAQ: CLVS), where she oversaw clinical development programs and managed Clinical and Pharmacokinetic functions, including the development of Rubraca®, a PARP inhibitor, developed with a diagnostic for BRCA and HRD. From 2003 to 2010, she was at Genentech, most recently as Group Medical Director, Global Clinical Development, leading a cross-functional group conducting Phase 2 and 3 trials of Avastin®.

Julie completed her medical and hematology-oncology training at the University of California, San Francisco, where she then served on faculty from 1993 to 2003. She received a B.S. from Duke University, and M.D. from Case Western Reserve University School of Medicine and was Board-certified in Hematology and Internal Medicine.

Jeff has over 20-years of experience in tumor biology, cancer pharmacology, & oncology discovery. He is co-founder and Senior Vice President and Chief Technology Officer and Head of Target Discovery and External Innovation at IDEAYA Biosciences. Prior to that he was Senior Vice President and Head of Biology at IDEAYA. Before his involvement with IDEAYA, he was VP of Biology at Seragon Pharmaceuticals, which was acquired by Roche/Genentech, where he oversaw all in vitro and in vivo biology and pharmacology that lead to the discovery of 2 novel, clinical stage selective estrogen receptor degraders (SERDs) developed as treatment for hormone receptor positive breast cancer. Previously, Jeff was Senior Director at Aragon Pharmaceuticals which was acquired by Johnson & Johnson. At Aragon, his team was central in pre-clinical development of the novel anti-androgen apalutamide (Erleada™), an FDA approved treatment for early-stage castration resistant prostate cancer. Previously, he was Associate Director of Biology at Apoptos, Inc. and before that a Principal Scientist and Head of Cancer Pharmacology at Kalypsys, Inc.

He did graduate studies at Princeton and University of California at Berkeley, the later from which he received a PhD in molecular and cell biology. He was a postdoctoral fellow and staff scientist at the University of California at San Francisco and is an author of publications in Annual Review of Cancer Biology, eLife, Science, Nature Genetics, Cancer Cell, Cancer Research and Cancer Discovery.

Mark has nineteen year’s experience in oncology drug development with broad experience ranging from target identification through biomarker development in registrational clinical trials. He is Vice President and head of Biomarkers and Synthetic Lethal Biology at IDEAYA. Prior to joining IDEAYA, Mark worked at Genentech for 14 years in positions of increasing responsibility in the Oncology Biomarker Development group, most recently as a Director and Principal Scientist. At Genentech his group was accountable for predictive and pharmacodynamic strategies for candidate therapeutics spanning cancer signaling through immuno-oncology, and was accountable for clinical biomarker strategies for over 20 development stage small molecule and antibody agents. His group developed clinical biomarker strategies for immune doublet combinations with the anti-PDL1 antibody Tecentriq, as well as phase III companion diagnostic strategies for the AKT inhibitor Ipatasertib and the MEK and BRAF inhibitors Cobimetinib and Vemurafenib. Mark also provided strategic leadership for the overall breast cancer biomarker strategy within the broader Roche organization. Prior to joining Genentech, Mark worked at Exelixis (NASDAQ: EXEL) from 1999 through 2004 in oncology target identification and validation, including the identification of synthetic lethal interactions with the tumor suppressor gene p53.

Mark received his PhD from Stanford University in 1997 for studies on genetic analysis of RAS/MAP kinase signaling. He completed postdoctoral studies at UC Berkeley in the laboratory of Joshua Kaplan. He has authored over 55 peer reviewed scientific manuscripts in journals including Nature Medicine, Nature Communications, Journal of Clinical Oncology, Cancer Cell and Clinical Cancer Research.

Paul is a life science executive with over 20 years of legal, financial, and management experience. Paul was previously with 5AM Ventures for over nine years in various leadership capacities including as Partner, General Counsel, and Chief Operating Officer. Paul serves as a Board of Director of Scientist.Com and was a founding Director at Cidara (NASDAQ: CDTX), Homology (NASDAQ: FIXX), and IDEAYA (NASDAQ: IDYA), as well was a Board Observer at RareCyte and other companies. He also held early management and operating rolls at Cidara, Entrada, IDEAYA and Homology. Prior to joining 5AM, Paul was Senior Vice President and General Counsel at Ethos Pharmaceuticals, Senior Vice President, General Counsel and Chief Patent Counsel at Ilypsa (acquired by Amgen) and Vice President, Chief Patent Counsel at Symyx (IPO). He earlier served in roles at Boeing and Wisconsin Electric.

Paul earned a B.S. in Chemical Engineering, University of Wisconsin, Madison, after which he served as a U.S. Naval Officer on USS NIMITZ. He received a J.D. from University of Wisconsin Law School and practiced intellectual property law as a Patent Attorney at Senniger Powers. Paul taught patent law, trade secrets law and licensing as an adjunct professor at University of Missouri and Santa Clara University. He also served on the Board of Directors of a regional non-profit, Save the Bay.

Bao has over 13-years of regulatory experience in oncology product development and extensive interactions with regulatory agencies, including the U.S. FDA, the European EMA, the Japan PMDA. She was Vice President and Head of Regulatory Affairs at Ignyta, where she helped drive entrectinib’s clinical development plan (from Phase 1/Expansion to registration-enabling single arm global Phase 2 basket trial) with potential to support both tissue specific and tissue agnostic indications. Prior to Ignyta, Bao served as Head of Regulatory Affairs at Aragon Pharmaceuticals, which was acquired by Johnson & Johnson, and at Seragon Pharmaceuticals, which was acquired by Roche/Genentech. While at Aragon, she led the regulatory development plan (from Phase 1/2 to initiation of global Phase 3 trial) of Erleada, the first FDA-approved therapy for non-metastatic castrate resistant prostate cancer using a novel clinical trial endpoint. Bao has nine years of earlier regulatory experience at Genentech, including as Global Regulatory Lead effecting the regulatory plan (from Phase 1/Expansion to registration-enabling single arm global Phase 2 trial) of Erivedge — the first FDA-approved therapy for advanced basal cell carcinoma, and held positions of increasing responsibilities for multiple oncology products, including Kadcyla, Gazyva, Tarceva and Herceptin. Bao also worked in oncology research at University of California, San Diego and University of California, San Francisco.

Bao earned her B.S., Biochemistry, from University of California, San Diego.

Andres has 10 years of progressive accounting and finance experience for public and private life science companies. He joined IDEAYA Biosciences as Controller in August 2016 and has served as Vice President, Finance since July 2019. Prior to joining IDEAYA, Andres served as Associate Director of Financial Planning & Analysis at Pharmacyclics, Inc. (NASDAQ: PCYC), where he helped lead the organization’s finance and operations efforts in support of the successful launch of blockbuster cancer drug, IMBRUVICA® (ibrutinib). He also played a key role in building the Company’s long-range planning and the integration activities into AbbVie, following Pharmacyclics’ $21 billion acquisition. Previously, Andres held roles at Theravance, Inc. (NASDAQ: THRX) and at PricewaterhouseCoopers’ audit and assurance practice where he focused on life science and venture capital clients.

Andres obtained his B.S. in Business Administration with a concentration in Corporate Financial Management from San Jose State University and is a Certified Public Accountant, licensed in the state of California.